Tech Center 1600 • Art Units: 1628
This examiner grants 34% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18141128 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE | Non-Final OA | Genzyme Corporation |
| 17275609 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | Final Rejection | Genentech, Inc. |
| 18210991 | NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18251129 | CRYSTALLINE FORM III OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 17757843 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17926074 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18257962 | COCRYSTAL OF A CDK INHIBITOR | Non-Final OA | AURIGENE ONCOLOGY LIMITED |
| 18265286 | 3-CYCLIC AMINE-INDOLE DERIVATIVES AS SEROTONERGIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | Non-Final OA | MINDSET PHARMA INC. |
| 18273942 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | Non-Final OA | The Regents of the University of Michigan |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Non-Final OA | Xenon Pharmaceuticals Inc. |
| 18003807 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | Non-Final OA | The Cleveland Clinic Foundation |
| 17434894 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | Final Rejection | The Trustees of The University of Pennsylvania |
| 18483225 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18222115 | NOVEL COMPOUNDS | Non-Final OA | AC Immune SA |
| 18266936 | TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES | Non-Final OA | Westlake University |
| 18749726 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | Final Rejection | United States Government as represented by the Department of Veterans Affairs |
| 18282068 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 17766113 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Final Rejection | Cavion, Inc. |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18480499 | INDAZOLE PYRIDONE COMPOUNDS AND USES THEREOF | Non-Final OA | Bluejay Therapeutics, Inc. |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | Non-Final OA | Amicus Therapeutics, Inc. |
| 18282082 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Non-Final OA | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED |
| 18466473 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Non-Final OA | RISEN (SUZHOU) PHARMA TECH CO., LTD. |
| 18119592 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Non-Final OA | RISEN (SUZHOU) PHARMA TECH CO., LTD. |
| 18460314 | CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE | Non-Final OA | Cytokinetics, Incorporated |
| 18547667 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF, AND INSECTICIDE AND ACARICIDE AND USE THEREOF | Non-Final OA | QINGDAO KANGQIAO PESTICIDES AND CHEMICALS GROUP CO., LTD. |
| 17426296 | 2H-INDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS FOR BRAIN CANCERS AND BRAIN METASTASES | Final Rejection | BETA PHARMA, INC. |
| 18255227 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Non-Final OA | NeuPharma, Inc |
| 18265192 | GENISTEIN FOR USE IN THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Non-Final OA | Delta 4 GmbH |
| 18253061 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | Non-Final OA | ELANCO TIERGESUNDHEIT AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy